The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2016

Filed:

Mar. 15, 2013
Applicants:

Roger Kingdon Craig, Cheshire, GB;

Franklin Gerardus Grosveld, Rotterdam, NL;

Richard Wilhelm Janssens, Rotterdam, NL;

Dubravka Drabek, Rotterdam, NL;

Tao Chen, Rotterdam, NL;

Ernie DE Boer, Rotterdam, NL;

Inventors:

Roger Kingdon Craig, Cheshire, GB;

Franklin Gerardus Grosveld, Rotterdam, NL;

Richard Wilhelm Janssens, Rotterdam, NL;

Dubravka Drabek, Rotterdam, NL;

Tao Chen, Rotterdam, NL;

Ernie De Boer, Rotterdam, NL;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/00 (2006.01); C07K 16/46 (2006.01); C07K 16/00 (2006.01); C07K 16/10 (2006.01); C07K 16/12 (2006.01); C07K 16/28 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 16/46 (2013.01); C07K 16/00 (2013.01); C07K 16/1018 (2013.01); C07K 16/1271 (2013.01); C07K 16/2896 (2013.01); C12N 15/8509 (2013.01); A01K 2267/01 (2013.01); C07K 2317/21 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework β-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.


Find Patent Forward Citations

Loading…